American Biogenetic Sciences, Inc. Introduces Products at Medica '97 Dusseldorf, Germany.BOSTON--(BW HealthWire)--Nov. 18, 1997-- Company Launches Products at the 29th World Forum for Sales to Doctors, Surgeons and Hospitals American Biogenetic bi·o·gen·e·sis also bi·og·e·ny n. 1. The principle that living organisms develop only from other living organisms and not from nonliving matter. 2. Generation of living organisms from other living organisms. 3. Sciences, Inc. (ABS) NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :MABXA, announced today that the Company is introducing two new clinical products at MEDICA medica (māˑ·dē·k '97, its patented in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. diagnostic tests, TpP(tm) (Thrombus thrombus /throm·bus/ (throm´bus) pl. throm´bi a stationary blood clot along the wall of a blood vessel, frequently causing vascular obstruction. Precursor Protein) and FiF(tm) (Functional Intact Fibrinogen Fibrinogen The major clot-forming substrate in the blood plasma of vertebrates. Though fibrinogen represents a small fraction of plasma proteins (normal human plasma has a fibrinogen content of 2–4 mg/ml of a total of 70 mg protein/ml), its conversion ) to the medical community. These two products have received clearance for marketing by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. . ABS' TpP(tm) is a diagnostic test of blood clot formation (thrombosis), and to monitor anticoagulant therapy. The test measures soluble fibrin fibrin: see blood clotting. polymers which have been shown to be elevated in patients at risk of thrombosis. The FiF(tm) assay provides physicians with a rapid and direct quantitative measurement of fibrinogen. Recent research papers have reported that fibrinogen level is an independent risk factor of cardiovascular disease. Robert J. Wolfgang, Director of the Office of International Trade and Business Development of the City of Boston stated, "We are very pleased that a Boston company, ABS, is at the forefront of the biotechnology industry in product development, and that they are a major player in this market on a global scale. We look forward to working with ABS as a major part of our international strategy in promoting Boston companies in the international marketplace." Stephen Ip, Ph.D., ABS' Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. , stated further, "In examining the most efficient way in which to introduce our product to the professional community, MEDICA '97 was the best choice. The size and scope of the show, as well as the types of individuals attending, offers ABS a unique opportunity to shine a spotlight on our innovative products. This forum will allow ABS to further develop its marketing and distribution efforts. In coordination with the City of Boston's Office of International Trade and MassPort, the company is confident that it will be able to enhance its products' distribution on a world wide basis." Medica '97 is the leading international medical trade fair and congress. In its twenty ninth year, the forum offers specific medical information on new product development. American Biogenetic Sciences, Inc., is a global biopharmaceutical and diagnostic company which conducts research and development throughout its Global Scientific Network(R) in the U.S., Europe, Israel and Russia. ABS is currently focused on the discovery and commercialization of products in the fields of cardiovascular medicine and neurobiology Neurobiology Study of the development and function of the nervous system, with emphasis on how nerve cells generate and control behavior. The major goal of neurobiology is to explain at the molecular level how nerve cells differentiate and develop their . The Company's enabling technology includes a patented Antigen-Free technology that allows the generation of highly specific monoclonal antibodies that cannot be acquired from conventional systems. Except for any historical information contained herein, the matters discussed in this press release contain forward looking statements that involve risks and uncertainties which are described in ABS' Form 10K and other reports filed with the SEC. -0- Visit us at MEDICA '97 - US Pavilion Hall 3, 3C 14-6 Visit our homepage on the Internet at http://www.mabxa.com CONTACT: Technical Contact: Ellena M. Byrne Executive Vice President 011-353-1-283-3325 embyrne@iol.com or Media and Investor Contact: Mitchell D. Benus Director of Investor Relations 516/789-2600 Fax: 516/789-1661 mbenus@mabxa.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion